Danaher (NYSE:DHR) Stock Price Expected to Rise, TD Cowen Analyst Says

Key Points

• TD Cowen has raised its price target on Danaher from $250.00 to $260.00, indicating a potential upside of 19.25% from the current stock price.
• Danaher recently reported a quarterly earnings of $1.89 EPS, exceeding the consensus estimate of $1.72, with revenue reaching $6.05 billion, a 4.4% increase year-over-year.
• Danaher has strong analyst support, with 18 analysts giving a "buy" rating and an average target price of approximately $248.92.

Danaher (NYSE:DHR - Get Free Report) had its price target boosted by research analysts at TD Cowen from $250.00 to $260.00 in a report issued on Wednesday,MarketScreener reports. The brokerage presently has a "buy" rating on the conglomerate's stock. TD Cowen's price target suggests a potential upside of 19.25% from the stock's current price.

DHR has been the topic of a number of other reports. Evercore ISI raised their price target on shares of Danaher from $226.00 to $245.00 and gave the company an "outperform" rating in a research report on Tuesday, October 7th. Rothschild Redb lowered shares of Danaher from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Danaher from $235.00 to $250.00 and gave the company a "buy" rating in a research report on Wednesday. Robert W. Baird lifted their target price on Danaher from $229.00 to $236.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 15th. Finally, Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a research note on Friday, July 11th. Eighteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and a consensus target price of $248.92.

Danaher Stock Down 1.2%

NYSE:DHR traded down $2.74 during trading hours on Wednesday, hitting $218.03. 560,296 shares of the company traded hands, compared to its average volume of 4,235,630. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The firm's 50-day simple moving average is $202.07 and its 200-day simple moving average is $197.59. Danaher has a one year low of $171.00 and a one year high of $260.88. The company has a market cap of $156.12 billion, a PE ratio of 46.39, a PEG ratio of 3.01 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the prior year, the company posted $1.71 earnings per share. The firm's revenue for the quarter was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts predict that Danaher will post 7.63 earnings per share for the current year.

Insider Activity

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 11.20% of the company's stock.

Institutional Trading of Danaher

Several hedge funds and other institutional investors have recently bought and sold shares of DHR. Norges Bank purchased a new stake in Danaher in the second quarter worth approximately $1,979,503,000. Nuveen LLC bought a new position in shares of Danaher during the first quarter valued at approximately $833,941,000. Viking Global Investors LP raised its holdings in shares of Danaher by 543.9% during the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate's stock valued at $574,351,000 after acquiring an additional 2,455,994 shares in the last quarter. Generation Investment Management LLP raised its holdings in shares of Danaher by 56.2% during the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate's stock valued at $980,914,000 after acquiring an additional 1,787,522 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after acquiring an additional 1,450,703 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.